Zimmer Biomet Holdings Inc (ZBH) is Upgraded by Citigroup to Neutral

Zimmer Biomet Holdings Inc (ZBH) was Upgraded by Citigroup to ” Neutral”. Earlier the firm had a rating of “Sell ” on the company shares. Citigroup advised their investors in a research report released on Nov 29, 2016.

Many Wall Street Analysts have commented on Zimmer Biomet Holdings Inc. Shares were Upgraded by Needham on Nov 1, 2016 to ” Strong Buy” and Lowered the Price Target to $ 148 from a previous price target of $150 .

On the company’s financial health, Zimmer Biomet Holdings Inc reported $1.79 EPS for the quarter, based on the information available during the earnings call on Oct 31, 2016. Analyst had a consensus estimate of $1.79. The company had revenue of $1832.80 million for the quarter, compared to analysts expectations of $1837.65 million. The company’s revenue was up 4.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.64 EPS.

Zimmer Biomet Holdings Inc opened for trading at $102 and hit $102.93 on the upside on Friday, eventually ending the session at $102.36, with a gain of 1.35% or 1.36 points. The heightened volatility saw the trading volume jump to 7,08,317 shares. Company has a market cap of $20,503 M.

In a different news, on Sep 9, 2016, Daniel E. Williamson (Group President) sold 2,716 shares at $129.96 per share price. According to the SEC, on Aug 24, 2016, Stuart G. Kleopfer (President, Americas) sold 3,397 shares at $129.71 per share price. On Aug 15, 2016, Tony W. Collins (VP, Controller and CAO) sold 1,287 shares at $129.29 per share price, according to the Form-4 filing with the securities and exchange commission.

Zimmer Biomet Holdings Inc. formerly Zimmer Holdings Inc. is a musculoskeletal healthcare company. The Company designs manufactures and markets orthopedic reconstructive products; sports medicine biologics extremities and trauma products; spine bone healing craniomaxillofacial and thoracic products; dental implants and related surgical products. The Company manages its operations through three geographic segments: the Americas comprising principally of the United States and includes other North Central and South American markets; Europe comprising principally of Europe and includes the Middle East and African markets; and Asia Pacific comprising primarily of Japan and includes other Asian and Pacific markets. The Company markets and sells products through three channels: direct to healthcare institutions such as hospitals or direct channel accounts; through stocking distributors and healthcare dealers and directly to dental practices and dental laboratories.

Zimmer Biomet Holdings Inc

Leave a Reply

Zimmer Biomet Holdings Inc - Is it time to Sell?

Top Brokerage Firms are advising their investors on Zimmer Biomet Holdings Inc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.